相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。A cohort study of acute pancreatitis in relation to exenatide use
D. D. Dore et al.
DIABETES OBESITY & METABOLISM (2011)
The Safety of Incretin-Based Therapies-Review of the Scientific Evidence
Daniel J. Drucker et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2011)
Effects of oral glucose-lowering drugs on long term outcomes in patients with diabetes mellitus following myocardial infarction not treated with emergent percutaneous coronary intervention - a retrospective nationwide cohort study
Casper H. Jorgensen et al.
CARDIOVASCULAR DIABETOLOGY (2010)
Acute Pancreatitis in Type 2 Diabetes Treated With Exenatide or Sitagliptin
Rajesh Garg et al.
DIABETES CARE (2010)
An assessment of adverse effects of vildagliptin versus comparators on the liver, the pancreas, the immune system, the skin and in patients with impaired renal function from a large pooled database of Phase II and III clinical trials
M. Ligueros-Saylan et al.
DIABETES OBESITY & METABOLISM (2010)
Assessing the cardio-cerebrovascular safety of vildagliptin: meta-analysis of adjudicated events from a large Phase III type 2 diabetes population
A. Schweizer et al.
DIABETES OBESITY & METABOLISM (2010)
Sitagliptin: review of preclinical and clinical data regarding incidence of pancreatitis
S. S. Engel et al.
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE (2010)
A Systematic Assessment of Cardiovascular Outcomes in the Saxagliptin Drug Development Program for Type 2 Diabetes
Robert Frederich et al.
POSTGRADUATE MEDICINE (2010)
Effect of saxagliptin monotherapy in treatment-naive patients with type 2 diabetes
J. Rosenstock et al.
CURRENT MEDICAL RESEARCH AND OPINION (2009)
The Efficacy and Safety of Saxagliptin When Added to Metformin Therapy in Patients With Inadequately Controlled Type 2 Diabetes With Metformin Alone
Ralph A. DeFronzo et al.
DIABETES CARE (2009)
Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trial
M. Jadzinsky et al.
DIABETES OBESITY & METABOLISM (2009)
Saxagliptin added to a submaximal dose of sulphonylurea improves glycaemic control compared with uptitration of sulphonylurea in patients with type 2 diabetes: a randomised controlled trial
A. R. Chacra et al.
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE (2009)
Saxagliptin Added to a Thiazolidinedione Improves Glycemic Control in Patients with Type 2 Diabetes and Inadequate Control on Thiazolidinedione Alone
Priscilla Hollander et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2009)
Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials
Kausik K. Ray et al.
LANCET (2009)
Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes
David M. Nathan et al.
DIABETES CARE (2009)
Rosiglitazone no longer recommended
[Anonymous]
LANCET (2008)
10-year follow-up of intensive glucose control in type 2 diabetes
Rury R. Holman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Improved meal-related insulin processing contributes to the enhancement of B-Cell function by the DPP-4 inhibitor vildagliptin in patients with type 2 diabetes
B. Ahren et al.
HORMONE AND METABOLIC RESEARCH (2007)
Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes
Steven E. Nissen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes
Daniel J. Drucker et al.
LANCET (2006)
Achievement of American Diabetes Association clinical practice recommendations among US adults with diabetes, 1999-2002 - The National Health and Nutrition Examination Survey
HE Resnick et al.
DIABETES CARE (2006)
Dose-response relation between sulfonylurea drugs and mortality in type 2 diabetes mellitus: a population-based cohort study
SH Simpson et al.
CANADIAN MEDICAL ASSOCIATION JOURNAL (2006)
Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events):: a randomised controlled trial
JA Dormandy et al.
LANCET (2005)
The relationship between dysglycaemia and cardiovascular and renal risk in diabetic and non-diabetic participants in the HOPE study: a prospective epidemiological analysis
HC Gerstein et al.
DIABETOLOGIA (2005)
Improved meal-related β-cell function and insulin sensitivity by the dipeptidyl peptidase-IV inhibitor vildagliptin in metformin-treated patients with type 2 diabetes over 1 year
B Ahrén et al.
DIABETES CARE (2005)
Enhancing incretin action for the treatment of type 2 diabetes
DJ Drucker
DIABETES CARE (2003)
Cardiovascular disease in type 2 diabetes: challenge for treatment and prevention
M Laakso
JOURNAL OF INTERNAL MEDICINE (2001)